DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for uterine corpus cancer — screening already-approved drugs against its 13-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleUterine corpus cancer maps to a 13-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for uterine corpus cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mutS homolog 2 (MSH2) — MSH2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8RB1 · 2.085 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Median survival for women with advanced or recurrent uterine cancer on most recent clinical trials from North America is approximately one year. A 2009 review of North American trials states that recurrent and metastatic endometrial cancer continues to pose a significant challenge, with median survival on recent trials only about one year. The review discusses developments in systemic therapy and new drug developments for recurrent endometrial cancer.
A 2010 review of uterine corpus cancer management in Korea discusses risks, prognostic factors, radiologic evaluation, prediction of lymph node metastasis, systematic lymphadenectomy, minimally invasive surgery, ovarian-saving surgery, fertility-sparing treatment, and adjuvant treatment. This review does not provide survival or response rate data.
A 1956 discussion of treatment for cancer of the uterine corpus evaluates total hysterectomy (abdominal or vaginal), radiotherapy, a combination of these two, and radical hysterectomy. The evaluation is based on applicability, primary mortality, and five-year survival without evidence of disease. The author notes there is no unanimity concerning the best therapy.
What is still missing is a clear, modern consensus on the optimal sequence or combination of systemic therapies for recurrent disease, and prospective data linking specific molecular subtypes to treatment response. No trial has yet demonstrated a regimen that reliably extends median survival beyond the current one-year benchmark in an unselected population. Adequately powered randomised trials with biomarker-driven patient stratification remain unfunded or incomplete.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Review of Anticancer Therapy · 2009 · 67 citations
Systemic therapy for recurrent endometrial cancer: a review of North American trials
AbstractWhile early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trials is only approximately 1 year. This review will discuss the developments of systemic therapy in recurrent endometrial cancer, focusing on North American trials, in particular those documenting recent progress in new drug developments, as well as the future of individualized treatment regimens.
Journal of Gynecologic Oncology · 2010 · 18 citations · open access
Current status in the management of uterine corpus cancer in Korea
AbstractUterine corpus cancer has increased in prevalence in Korean women over the last decade. Recently, elegant studies have been reported from many institutes. To improve treatment strategies, a review of our own data is warranted. This work will discuss the risks and prognostic factors for uterine corpus cancer, and the radiologic evaluation, prediction of lymph node metastasis, systematic lymphadenectomy, minimally invasive surgery, ovarian-saving surgery, fertility-sparing treatment, and adjuvant treatment in women with uterine cancer.
New England Journal of Medicine · 1956 · 11 citations
Treatment of Choice in Cancer of the Uterine Corpus
AbstractCANCER of the uterine corpus can be successfully treated in a number of ways. However, there is no unanimity concerning the best therapy. The following discussion is intended to evaluate the different methods and to aid in the development of a plan for the treatment of this disease.The types of treatment now employed are: total hysterectomy by either the abdominal or the vaginal route; radiotherapy; a combination of these two; and radical hysterectomy. These can be evaluated by their applicability, primary mortality and five-year survival without evidence of disease. Because the various methods of treatment are not equally applicable, . . .
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
